Respiratory Syncytial Virus Market to Surge at a CAGR of 13.1% During the Study Period (2019-2032), Predicts DelveInsight

The respiratory syncytial virus market is expected to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. 

LAS VEGAS, Jan. 16, 2023 /PRNewswire/ -- DelveInsight's Respiratory Syncytial Virus Market Insights report includes a comprehensive understanding of current treatment practices, respiratory syncytial virus emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Respiratory Syncytial Virus Market Report

• As per DelveInsight analysis, the respiratory syncytial virus market size in the 7MM was approximately USD 850 million in 2021.
• According to the assessment done by DelveInsight, the estimated total respiratory syncytial virus incident cases in the 7MM were approximately 4.2 million in 2021. 
• Leading respiratory syncytial virus companies such as Bavarian Nordic, Pfizer, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, and others are developing novel respiratory syncytial virus drugs that can be available in the respiratory syncytial virus market in the coming years.
• The promising respiratory syncytial virus therapies in the pipeline include MVA-BN-RSV Vaccine, RSVpreF (PF-06928316), RSVPreF3 (GSK3844766A) Vaccine, VAC 18193 (Ad26.RSV.preF), MEDI8897 (nirsevimab), mRNA-1345, RV521/PF-07923568 (Sisunatovir), and others.
• In September 2022, CHMP recommended approval of BEYFORTUS (nirsevimab) for the prevention of RSV disease in infants in Europe. 
• In June 2022, Pfizer completed the acquisition of ReViral.
•  In August 2020, the US FDA granted the drug Fast track designation to treat patients with serious RSV infection.

Discover which therapies are expected to grab the major respiratory syncytial virus market share @ Respiratory Syncytial Virus Market Report

Respiratory Syncytial Virus Overview

The respiratory syncytial virus (RSV) is a highly contagious respiratory virus. It belongs to the genus Pneumovirus, which is part of the family Paramyxoviridae. Virus particles are enveloped and pleomorphic, forming irregular spherical particles with diameters of 100-350 nm and long filamentous fibers with diameters of 60-200 nm and lengths of 10 mm.

Signs and symptoms of RSC infection typically appear 46 days after virus exposure. RSV typically causes mild cold-like symptoms in adults and older children. These respiratory syncytial virus symptoms may include a stuffy or runny nose, a dry cough, a low-grade fever, sore throat, sneezing, and a headache. RSV testing is not always necessary. Several types of laboratory tests are used for respiratory syncytial virus diagnosis if required. The rapid diagnostic test is the most commonly used.

Respiratory Syncytial Virus Epidemiology Segmentation

DelveInsight estimates that there were approximately 4.2 million incident cases of respiratory syncytial virus in the 7MM in 2021.

As per the analysis, the total incident cases of RSV were found highest in the below 5 years category, followed by 65 years and above, and the least number of cases were found in 5 to 64 years age group in the 7MM.

The respiratory syncytial virus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases
• Age-specific Incident Cases

Download the report to understand which factors are driving respiratory syncytial virus epidemiology trends @ Respiratory Syncytial Virus Epidemiological Insights

Respiratory Syncytial Virus Treatment Market 

RSV infection is currently treated only with supportive care and prophylactic antibody use. When necessary, it may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation. Albuterol and other bronchodilators have long been used and studied in RSV bronchiolitis. Unfortunately, there is no universal agreement on their effectiveness. Despite extensive research into the effects of bronchodilators on young infants and children, there are very few studies or recommendations available for adult patients with RSV infection. Because adults with RSV lower respiratory infections frequently have co-infections and multiple comorbidities, developing a guideline that applies to such a diverse population is much more difficult.

Nebulized 3% saline solution has also been studied as a treatment for RSV bronchiolitis. Although there may be a role for nebulized hypertonic saline in the inpatient setting, its acute use in the ED appears to be limited in the current studies. Corticosteroids had no statistically significant benefit on hospital stay or clinical outcomes when compared to placebo.

The US FDA has approved Palivizumab (a monoclonal antibody that targets the RSV F protein) to prevent serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease. Palivizumab (SYNAGIS) patents in the United States expired in October 2015. There are currently no biosimilars available for this drug.

To know more about respiratory syncytial virus guidelines, visit @ Respiratory Syncytial Virus Management 

Respiratory Syncytial Virus Pipeline Therapies and Key Companies

• MVA-BN-RSV Vaccine: Bavarian Nordic
• RSVpreF (PF-06928316): Pfizer
• RSVPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
• VAC 18193 (Ad26.RSV.preF): Janssen
• MEDI8897 (nirsevimab): Sanofi/AstraZeneca
• mRNA-1345: Moderna
• RV521/PF-07923568 (Sisunatovir): ReViral/Pfizer

Learn more about the FDA-approved respiratory syncytial virus drugs @ Drugs for Respiratory Syncytial Virus Treatment 

Respiratory Syncytial Virus Market Dynamics

The respiratory syncytial virus market is expected to grow due to factors like increase in the patient pool and expected entry of emerging therapies. While no RSV vaccine is currently available; however, many promising vaccine candidates are in clinical trials, which will be in the respiratory syncytial virus market soon. A safe and effective vaccine could save many lives and reduce hospitalizations significantly.

Currently, an approved drug known as palivizumab (SYNAGIS) protects premature infants and young children with certain heart and lung conditions. During RSV season, palivizumab is administered in a series of monthly injections. Moreover, rapid identification of RSV infection, which can aid in early detection and reduce the burden. While there are rapid tests for RSV, a clinical diagnosis can be made in otherwise healthy children. 

However, several factors will likely hamper the respiratory syncytial virus market growth. RSV is a common cause of viral respiratory disease in adults and occurs primarily in the winter months in the United States. It is a significant cause of morbidity and mortality, particularly in the young and old. There is little knowledge about the best adult therapy. Bronchodilators and steroids are generally ineffective in infants.

Despite its high prevalence and potential severity in high-risk infant populations worldwide, many parents and families are still unaware of RSV. There is currently no specific RSV antiviral or vaccine in the respiratory syncytial virus market for any age group, which may discourage the use of RSV diagnostic testing because the results do not change clinical management. There are only two FDA-approved RSV drugs in the respiratory syncytial virus market: palivizumab, a monoclonal antibody used to prevent RSV in high-risk children, and ribavirin, which is used to treat severe RSV disease. Both of these respiratory syncytial virus medications have dubious efficacy.

Scope of the Respiratory Syncytial Virus Market Report

• Therapeutic Assessment: Respiratory Syncytial Virus current marketed and emerging therapies
• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Respiratory Syncytial Virus Market Access and Reimbursement

Discover more about respiratory syncytial virus drugs in development @ Respiratory Syncytial Virus Clinical Trials

Table of Contents

Related Reports

Respiratory Syncytial Virus Epidemiology Forecast

Respiratory Syncytial Virus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted respiratory syncytial virus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Respiratory Syncytial Virus Pipeline

Respiratory Syncytial Virus Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key respiratory syncytial virus companies, including Moderna, ReViral, Swedish Orphan Biovitrum AB (SOBI), among others.

Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute respiratory distress syndrome companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, among others.

Acute Respiratory Distress Syndrome Pipeline

Acute Respiratory Distress Syndrome Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, among others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic obstructive pulmonary disease companies, including  AstraZeneca, GlaxoSmithKline, Theravance, Inc, Innoviva, Chiesi Farmaceutici, among others.

Chronic Obstructive Pulmonary Disease Pipeline

Chronic Obstructive Pulmonary Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic obstructive pulmonary disease companies, including  AstraZeneca, GlaxoSmithKline, Theravance, Inc, Innoviva, Chiesi Farmaceutici, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market

Related Healthcare Blogs

Promising Therapies in the ARDS Market

Rising Acute Respiratory Distress Syndrome Prevalence

ARDS Market Outlook

Factors Contributing to COPD Prevalence

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us

Shruti Thakur  
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg